Contribution of SELENOF to the Disproportionate Mortality Experienced by African American Men Due to Prostate Cancer
Abstract
Prostate cancer disproportionately affects African American men and our laboratory has determined that an at-risk polymorphism in the gene for SELNOF is 10-times more frequent in the genomes of African Americans and this genetic variation is likely to result in lower SELENOF levels in tissues. It remains possible that reduced levels of SELENOF are not contributing to cancer progression but are just a bystander to the changes that occur during malignancy. The most significant finding during this funding period is that there is a block to the translation of SELENOF in prostate cancer cells. SELENOF expression constructs that failed to generate SELENOF in prostate cells were able to support the production of SELENOF from an inducible promoter in a different cell type. MCF-7 human breast cancer cells engineered to over-expressed SELENOF. These cells exhibited the opposite effects of prostate cells in which SELENOF levels were reduced. The parameters examined included growth rate, anchorage independent growth and oxygen consumption. These results contribute to the assignment of SELENOF as a tumor suppressor and support the hypothesis that the genetics of SELENOF is a factor in the disparity in prostate cancer mortality experienced by African Americans.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2020
- Accession Number
- AD1109485
Entities
People
- Alan M Diamond
Organizations
- University of Illinois at Chicago